Cotreatment with interferon-α and γ reduces liver fibrosis in a rat model

Hepatology Research

Volumn 28, Issue 3, 2004, Pages 146-154

  Takahara, Terumi ^a   Sugiyama, Kota ^b   Zhang, Li Ping ^a   Ando, Osamu ^c   Fujii, Mitsukiyo ^c   Yata, Yutaka ^a   Bo, Jin ^a   Xue, Feng ^a   Minemura, Masami ^a   Watanabe, Akiharu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

Antiviral cytokine; Immunomodulatory cytokine; Matrix metalloproteinase; MMP 2; TIMP 1; TIMP 2; Tissue inhibitor of matrix metalloproteinase

Indexed keywords

AMINOTRANSFERASE; CALCIUM CHLORIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DESMIN; GELATINASE A; HYALURONIC ACID; HYDROXYPROLINE; MESSENGER RNA; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIGITAL COMPUTER; DISEASE EXACERBATION; DRUG DOSE REGIMEN; HEPATITIS; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; LIVER FIBROSIS; MALE; MONOTHERAPY; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 10744220333     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2003.11.003     Document Type: Article

References (48)

1. Hoofnagle J.H. Mellen K.D. Jones D.B. Rustgi V. Di Bisceglie A. Peters M. et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report N. Engl. J. Med. 315 1986 1575-1578
2. Hirayama N. Hayashi N. Kasahara A. Hagiwara H. Takehara T. Haruna Y. et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha J. Hepatol. 22 1995 135-142
3. Marcellin P. Boyer N. Gervais A. Martinot M. Pouteau M. Castelnau C. et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy Ann. Intern. Med. 127 1997 875-881
4. Manabe N. Chevallier M. Chossegros P. Causse X. Guerret S. Trepo C. et al. Interferona-2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitive histological evaluation Hepatology 18 1993 1344-1349
5. Shiratori Y. Imazeki F. Moriyama M. Yano M. Arakawa Y. Yokosuka O. et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy Ann. Intern. Med. 132 2000 517-524
6. Abe S. Tabaru A. Ono M. Tai M. Narita R. Moriyama A. et al. High-dose interferon-alpha therapy lowers the levels of serum fibrogenesis markers over 5 years in chronic hepatitis C Hepatol. Res. 25 2003 22-31
7. Sobesky R. Mathurin P. Charlotte F. Moussalli J. Olivi M. Vidaud M. et al. Modeling the impact of interferon alpha treatment of liver fibrosis progression in chronic hepatitis C: a dynamic view Gastroenterology 116 1999 378-386
8. Mallat A. Preaux A. Blazejewski S. Rosenbaum J. Dhumeaux D. Mavier P. Interferon alpha and gamma inhibit proliferation and collagen systhesis of human ito cells in culture Hepatology 21 1995 1003-1010
9. Inagaki Y, Nemoto T, Nakao A. Transcriptional activation of type I collagen gene during hepatic fibrogenesis. In: Okazaki I, Ninomiya Y, Friedman S, Tanikawa K, editors. Extracellular matrix and the liver-approach to gene therapy. New York: Academic press; 2003.
10. Saez-Royuela F. Porres J.C. Moreno A. Castillo I. Martinez G. Galiana F. et al. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial Hepatology 13 1991 327-331
11. Kakumu S. Ishikawa T. Mizokami M. Orido E. Yoshioka K. Wakita T. et al. Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon J. Med. Virol. 35 1991 32-37
12. Lau J.Y. Lai C.L. Wu P.C. Chung H.T. Lok A.S. Lin H.J. A randomised controlled trial of recombinant interferon-gamma in Chinese patients with chronic hepatitis B virus infection J. Med. Virol. 34 1991 184-187
13. Yuan W. Yufit T. Li L. Mori Y. Chen S. Varga J. Negative modulation of a1(I) procollagen gene expression in human skin fibroblasts: transcriptional inhibition by interferon-γ J. Cell Physiol. 179 1999 97-108
14. Jamenez S.A. Freundlich B. Rosenbloom J. Selective inhibition of human deploid fibroblast collagen sysnthesis by interferons J. Clin. Invest. 74 1984 1112-1116
15. Baroni G.S. D'Ambrosio L. Curto P. Casini A. Mancini R. Jezequel A.M. et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis Hepatology 23 1996 1189-1199
16. Sakaida I. Uchida K. Matsumura Y. Okita K. Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-beta1 expression in pig serum-induced rat liver fibrosis in vivo J. Hepatol. 28 1998 471-479
17. Katayama K. Kasahara A. Sasaki Y. Kashiwagi T. Naito M. Masuzawa M. et al. Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance J. Viral Hepatol. 8 2001 180-185
18. Kumashiro R. Ide T. Sasaki M. Murashima S. Suzuki H. Hino T. et al. Interferon-γ brings additive anti-viral environment when combined with interferon-α in patients with chronic hepatitis C Hepatol. Res. 22 2002 20-26
19. Yamamoto S. Yano H. Sanou O. Ikegami H. Kurimoto M. Kojiro M. Different antiviral activities of IFN-alpha subtypes in human liver cell lines: synergism between IFN-alpha2 and IFN-alpha 8 Hepatol. Res. 24 2002 99-106
20. Zhang L.P. Takahara T. Yata Y. Furui K. Jin B. Kawada N. et al. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells J. Hepatol. 31 1999 703-711
21. Kivirikko K.I. Laitinen O. Prockop D.J. Modifications of a specific assay for hydroxyproline in urine Anal. Biochem. 19 1967 249-255
22. Takahara T. Furui K. Funaki J. Nakayama Y. Itoh H. Miyabayashi C. et al. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats Hepatology 21 1995 787-795
23. Takahara T. Furui K. Yata Y. Jin B. Zhang L.P. Nambu S. et al. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers Hepatology 26 1997 1521-1529
24. Fort P. Marty L. Piechaczyk M. El Sabrouty S. Dani C. Jeanteur P. et al. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family Nucleic Acids Res. 13 1985 1431-1442
25. Genovese C. Rowe D. Kream B. Construction of DNA sequences complementary to rat A1 and A2 collagen mRNA and their use in studying regulation of type I collagen synthesis by 1,25-Dihydroxyvitamin D Biochemistry 23 1984 6210-6216
26. Sato H. Kida Y. Mai M. Endo Y. Sasaki T. Tanaka J. et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells Oncogene 7 1992 77-83
27. Quinn C.O. Scott D.K. Brinckerhoff C.E. Matrisian L.M. Jeffrey J.J. Partridge N.C. Rat collagenase. Cloning, amino acid sequence comparison, and parathyroid hormone regulation in osteoblastic cells J. Biol. Chem. 265 1990 22342-22347
28. Derynck R. Jarrett J.A. Chen E.Y. Eaton D.H. Bell J.R. Assoian R.K. et al. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells Nature 316 1985 701-705
29. Yasuda H. Imai E. Shiota A. Fujise N. Morinaga T. Higashio K. Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats Hepatology 24 1996 636-642
30. Strongin A.Y. Collier I. Bannikov G. Marmer B.L. Grant G.A. Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase J. Biol. Chem. 270 1995 5331-5338
31. Iredale J.P. Benyon R.C. Pickering J. McCullen M. Northrop M. Pawley S. et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors J. Clin. Invest. 102 1998 538-549
32. Murphy F.R. Issa R. Zhou X. Ratnarajah S. Nagase H. Arthur M.J. et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition. Implication for reversibility of liver fibrosis J. Biol. Chem. 277 2002 11069-11076
33. Bueno M.R. Daneri A. Armendariz-Borunda J. Cholestasis-induced fibrosis is reduced by interferon alpha-2a and is associated with elevated liver metalloprotease activity J. Hepatol. 33 2000 915-925
34. Lu G. Shimizu I. Cui X. Itonaga M. Tamaki K. Fukuno H. et al. Interferon-α enhances biological defense activities agaist oxidative stress in cultures rat hepatocytes and hepatic stellate cells J. Med. Invest. 49 2002 172-181
35. Kasahara A. Hayashi N. Mochizuki K. Oshita M. Katayama K. Kato M. et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C Relationship to interferon response J. Hepatol. 26 1997 574-583
36. Sakaida I. Hironaka K. Uchida K. Suzuki C. Kayano K. Okita K. Interferon γ- but not α-treatment prevents fibrosis by inhibiting procollagen and tissue inhibitor of metalloproteinase-1 gene expression in pig serum-induced rat liver fibrosis in vivo Hepatol. Res. 12 1998 59-67
37. Baroni G.S. D'Ambrosio L. Curto P. Casini A. Mancini R. Jezequel A.M. et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis Hepatology 23 1996 1189-1199
38. Frebourg T. Delpech B. Bercoff E. Senant J. Bertrand P. et al. Serum hyaluronate in liver diseases: study by enzymoimmunological assay Hepatology 6 1986 392-395
39. Qi Z. Atsuchi N. Ooshima A. Takeshita A. Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat Proc. Natl. Acad. Sci. U.S.A. 96 1999 2345-2349
40. Nakamura T. Sakata R. Ueno T. Sata M. Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats Hepatology 32 2000 247-255
41. Ueno H. Sakamoto T. Nakamura T. Qi Z. Astuchi N. Takeshita A. et al. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats Hum. Gene Ther. 11 2000 33-42
42. Okuno M. Akita K. Moriwaki H. Kawada N. Ikeda K. Kaneda K. et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta Gastroenterology 120 2001 1784-1800
43. Jonsson J.R. Clouston A.D. Ando Y. Kelemen L.I. Horn M.J. Adamson M.D. et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis Gastroenterology 121 2001 148-155
44. Yoshiji H. Kuriyama S. Yoshii J. Ikenaka Y. Noguchi R. Nakatani T. et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats Hepatology 34 2001 745-750
45. Cho J.J. Hocher B. Herbst H. Jia J.D. Ruehl M. Hahn E.G. et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis Gastroenterology 118 2000 1169-1178
46. Ueki T. Kaneda Y. Tsutsui H. Nakanishi K. Sawa Y. Morishita R. et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats Nat. Med. 5 1999 226-230
47. Yoshida H. Shiratori Y. Moriyama M. Arakawa Y. Ide T. Sata M. et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy Ann. Intern. Med. 131 1999 174-181
48. Okanoue T. Itoh Y. Kirishima T. Daimon Y. Toyama T. Morita A. et al. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients Hepatol. Res. 23 2002 62-77